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Idiopathic pulmonary fibrosis is a chronic disease of unknown etiology that usually has a progressive course and
is commonly associated with a poor prognosis. The main symptoms of idiopathic pulmonary fibrosis, including
progressive dyspnea and dry cough, are often nonspecific. Chest high-resolution computed tomography is the
primary modality used in the initial assessment of patients with suspected idiopathic pulmonary fibrosis and
may have considerable influence on subsequent management decisions. The main role of computed tomo-
graphy is to distinguish chronic fibrosing lung diseases with a usual interstitial pneumonia pattern from those
presenting with a non-usual interstitial pneumonia pattern, suggesting an alternative diagnosis when possible.
A usual interstitial pneumonia pattern on chest tomography is characterized by the presence subpleural and
basal predominance, reticular abnormality honeycombing with or without traction bronchiectasis, and the
absence of features suggestive of an alternative diagnosis. Idiopathic pulmonary fibrosis can be diagnosed
according to clinical and radiological criteria in approximately 66.6% of cases. Confirmation of an idiopathic
pulmonary fibrosis diagnosis is challenging, requiring the exclusion of pulmonary fibroses with known causes,
such as asbestosis, connective tissue diseases, drug exposure, chronic hypersensitivity pneumonitis, and other
forms of idiopathic interstitial pneumonitis. The histopathological hallmark of usual interstitial pneumonia is a
heterogeneous appearance, characterized by areas of fibrosis with scarring and honeycombing alternating with
areas of less affected or normal parenchyma. The aim of this article was to review the clinical, radiological, and
pathological features of idiopathic pulmonary fibrosis and of diseases that might mimic idiopathic pulmonary
fibrosis presentation.
KEYWORDS: Differential Diagnosis; Idiopathic Pulmonary Fibrosis; Radiology; Pathology; Interstitial Lung
Diseases.
’ INTRODUCTION AND HISTORY
Idiopathic pulmonary fibrosis (IPF) is a chronic disease
of unknown etiology that usually has a progressive course,
and IPF is commonly associated with a poor prognosis.
Although IPF has been described extensively in the litera-
ture, some controversy exists regarding its history. The first
description of IPF as a new clinical and pathological entity is
usually attributed to a 1933 report by Hamman & Rich (1).
Nevertheless, many reports in German have previously
published descriptions of autopsy findings that were consis-
tent with IPF (2). Patients presented with progressively wors-
ening cough and dyspnea, and autopsies usually revealed
hypertrophied right ventricles, small rigid lungs with wid-
ened and thickened bronchioli, and an increased quantity
of interstitial tissue without pleural adhesions (2). In these
German reports, different terms were proposed to describe
these interstitial changes, namely, cirrhosis cystica pulmonum
and lymphangitis reticularis pulmonum (2).
Clinical and laboratory assessment
A detailed clinical assessment is essential for the diagnosis
of patients with interstitial lung diseases (ILDs) and for the
diagnostic confirmation of IPF. A detailed investigation of
exposure to external agents, such as mold, birds, and drugs,
should be performed. Evidence of extrapulmonary manifes-
tations, such as arthralgia, Raynaud phenomenon, dry mouth
and eyes, and skin lesions, are essential to the approach
for ILDs as these factors can be helpful in establishingDOI: 10.6061/clinics/2019/e225
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the diagnosis of connective tissue diseases (CTDs), which can
also present a usual interstitial pneumonia (UIP) pattern.
An investigation of the family history of lung disorders is
also recommended because CTDs and hereditary diseases
are potential etiologies of ILDs (3-5).
IPF mainly affects patients in their sixth and seventh decades
of life, with a higher prevalence in males and smokers or
former smokers, and IPF affects the lungs exclusively (3).
Gastroesophageal reflux is a common association (3,6).
The main symptoms of IPF, including progressive dyspnea
and dry cough, are often nonspecific (6). Frequent signs on
physical examination include the presence of bilateral inspi-
ratory crackles (Velcro-like) predominantly in the lower lung
zones, and digital clubbing (3,5). Pulmonary function tests
(PFTs) in IPF are characterized by a restrictive pattern com-
bined with a decreased diffusing capacity. Diminished exer-
cise performance and hypoxemia at rest or during exercise
may be found (7).
Serological analyses, including tests for rheumatoid factor
(RF), anti-cyclic citrullinated peptide, and anti-nuclear anti-
body (ANA), are helpful in the differential diagnosis as
the UIP pattern can also be found in CTDs (7,8). How-
ever, mildly positive ANA and/or RF serology can be found
in IPF (5).
Computed tomography signs (definition, accuracy,
interobserver agreement and differential diagnosis)
A ground-glass opacity (GGO), a reticular pattern, traction
bronchiectasis, and honeycombing are among the most com-
mon features of ILDs on high-resolution computed tomogra-
phy (HRCT), and physicians should be familiar with the
definitions, accuracies, and differential diagnoses of these
features for the diagnostic work-up.
Ground-glass opacity
On computed tomography (CT) imaging, GGO presents as
a dense area of increased opacity within the lungs that
conserves bronchial and vascular margins (Figure 1A) (9).
GGO is less hazy than consolidation, in which bronchovas-
cular margins cannot be distinguished. GGO can be due to
the partial filling of airspaces, interstitial thickening (as a
result of fluid, cells, and/or fibrosis), the partial collapse of
alveoli, an increased capillary blood volume, or a combina-
tion of these, whereas all are related to the common partial
displacement of air (9). Good interobserver agreement has
been reported in the detection of GGO (kappa value, 0.78-
0.90) (10).
Reticular pattern
A reticular pattern is defined as a collection of several small
linear opacities that resemble a net-like aspect (Figure 1B) (9).
The components of a reticular pattern are clearly observed on
thin-section CT, and they can represent interlobular septal
thickening, intralobular lines, or the cyst walls of honeycomb-
ing. This finding is usually associated with ILD, but conges-
tion and infections (e.g., viral) are also important differential
diagnoses (9).
Honeycombing
Honeycombing is defined as clustered cystic airspaces
that are usually subpleural with well-defined walls and
diameters ranging from 0.3-1 cm, reaching 2.5 cm is rare
cases (Figure 1C) (9). Commonly considered specific for IPF,
honeycombing is an essential criterion for UIP diagnosis, and
the terminology should be used carefully as it may directly
influence patient management (11). Centrilobular emphy-
sema, traction bronchiectasis, and cystic lung disease should
be included in the differential diagnoses. Interobserver agre-
ement for honeycombing is moderate (kappa=0.59±0.12).
In a study by Watadani et al., there was disagreement on
the identification of honeycombing in 29% of cases due to
the co-existence of traction bronchiectasis, large cysts, and
overlapping pulmonary emphysema (12).
Traction bronchiectasis
Traction bronchiectasis and bronchiolectasis represent
nonuniform bronchial and bronchiolar dilatation, respec-
tively (Figure 1A) (9). Dilated airways can also present as
cysts (bronchi) or microcysts (bronchioles in the lung
periphery). In IPF, traction bronchiectasis is better explained
as a result of bronchiolar proliferation instead of utter
mechanical traction (13). Recent studies have suggested that
traction bronchiectasis and honeycombing are parts of a
spectrum of the presentation of a singular and continuous
mechanism of bronchiolar dysplastic proliferation in IPF
(13,14). On the other hand, in nonspecific interstitial pneu-
monia (NSIP), bronchocentricity is predominant, and trac-
tion bronchiectasis is exclusively surrounded by fibrotic
tissue, characteristics that suggest the mechanical traction
as the main component in the development of traction bron-
chiectasis in NSIP (13,14). Interobserver agreement for trac-
tion bronchiectasis is moderate, with kappavalues ranging
from 0.24 to 0.42 (11).
Idiopathic pulmonary fibrosis
Computed tomography diagnostic criteria (usual inter-
stitial pneumonia). Chest HRCT plays an essential role in
the initial assessment of suspected IPF, considerably influen-
cing subsequent management decisions. The primary role of
HRCT is to distinguish chronic fibrosing lung diseases with
an UIP pattern from those presenting a non-UIP pattern, sug-
gesting an alternative diagnosis when possible. The most
common HRCT protocol used to evaluate diffuse lung
diseases is a volumetric acquisition of thin sections (generally
o1.5 mm), combined with a high spatial frequency recon-
struction algorithm (15). The 2018 ATS/ERS/JRS/ALAT
guidelines for diagnosis of IPF (6) suggested four diagnostic
entities: (a) UIP, (b) probable UIP, (c) indeterminate for UIP,
and (d) alternative diagnosis (Table 1). The HRCTcriteria for a
UIP diagnosis include the presence of honeycombing with or
without peripheral traction bronchiectasis or bronchiolectasis
and a basal and subpleural distribution (6). Although GGO is
common in UIP, it must be less extensive than the reticulation
and be superimposed on a fine reticular pattern to be
characterized as an UIP pattern (6). Another common feature
on HRCT is mediastinal and hilar lymph node enlargement,
which is present in up to 70% to 86% of patients with a UIP
pattern (typically o15 mm) (16).
In approximately 66.6% of cases, a diagnosis of IPF can be
performed based only on clinical and radiological features
(17). The morbidity and mortality associated with lung bio-
psies in patients with fibrosis are high, at approximately
3-4% in most studies (18). Several recent reports suggest
that surgical lung biopsy is unnecessary for an IPF diagnosis
in some cases with possible UIP patterns on HRCT in the
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Figure 1 - Common features on high-resolution computed tomography in interstitial lung diseases. (a) Images from a 63-year-old
female presenting a nonspecific interstitial pneumonia pattern. There are predominant areas of ground-glass opacities, with
some traction bronchiectasis and cortical interlobular septal thickening. (b) Images from a 61-year-old male with idiopathic
pulmonary fibrosis. There are diffuse areas of interlobular septal thickening, predominantly in the cortical lung zones. (c) Images
from a 56-year-old female with idiopathic pulmonary fibrosis. There are extensive areas of honeycombing, with some interlobular
septal thickening.
Table 1 - HRCT Criteria for the UIP Pattern.









- Reticular abnormality with
peripheral traction
bronchiectasis
- May have mild GGO
- Predominantly subpleural and
basal distribution
- Mild reticulation, mild GGO or
distortion
- CT features that do not
suggest any specific etiology
- Distribution other than subpleural/basal
- Extensive GGO (extension 4 reticular
abnormality)
- Profuse micronodules (bilateral,
predominantly upper lobes)
- Discrete cysts (multiple, bilateral, apart from
areas of honeycombing)
- Diffuse mosaic attenuation/air-trapping
(bilateral, in three or more lobes)
- Consolidation in bronchopulmonary segment(s)/
lobe(s)
CT: Computed Tomography; GGO: Ground-glass Opacity; UIP: Usual Interstitial Pneumonia; 4: Greater Than.
Adapted from Raghu et al. (6).
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appropriate clinical settings at specialized centers (19).
A confident diagnosis of UIP based on HRCT is accurate in
80% to 95% of cases using pathology as a reference (20).
In multiple studies assessing the CT accuracy for an IPF dia-
gnosis, pathology was considered a gold standard. However,
there is substantial interobserver variation among patholo-
gists in the assessment of non-neoplastic lung disease (21).
An interobserver variation over 50% has been reported for
the pathological diagnosis of NSIP and its distinction from
UIP (21).
Histopathology diagnostic criteria (usual interstitial
pneumonia). The main histopathologic feature and diag-
nostic criterion of UIP is a patchy presentation comprising
affected zones of fibrosis with scarring and honeycombing
alternating with zones of less affected or healthy tissue
(Table 2) (Figure 2C) (22). These findings usually prevail
in the subpleural and paraseptal parenchyma. Inflammation
is commonly absent or mild, consisting of an irregular
interstitial infiltrate of lymphocytes and plasma cells asso-
ciated with the hyperplasia of type 2 pneumocytes and the
bronchiolar epithelium. Although the fibrotic areas consist
primarily of dense collagen, the diffuse convex subepithelial
foci of proliferating fibroblasts and myofibroblasts are typical
findings (fibroblast foci). These should be differentiated from
fibroblastic alveolar plugs of organizing pneumonia. While
the former is always within the interstitial spaces, the latter is
associated with polypoid intrusions into the alveolar space.
Zones of honeycombing are formed by cystic fibrotic
airspaces that are commonly lined by a bronchiolar epithelium
and filled with mucus and inflammatory cells (22).
Pathogenesis. The pathogenesis of IPF has been dis-
cussed for several years, and one of the most accepted views
is that the initial inflammatory events might initiate a dys-
regulated fibroblast-mediated wound-healing response that
Figure 2 - Images from a 53-year-old male with idiopathic pulmonary fibrosis. (a) Axial and (b) coronal computed tomography images
demonstrating areas of honeycombing, reticulation and subpleural predominance. (c) Histopathology images demonstrating areas of
marked fibrosis, with architectural distortion and fibroblast foci, alternating with areas of normal parenchyma.
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can be sustained by several factors, leading to lung fibrosis
(23). One of the most accepted models is the ‘‘alveolar stem
cell exhaustion’’ model, which suggests that an accelerated
parenchymal senescence that is determined by predisposing
factors, such as genetic mutations or variations and telome-
rase dysfunction, together with environmental exposures,
such as tobacco smoke, can severely compromise the regen-
erative potential of parenchymal epithelial stem cells (13,24,25).
This epithelial damage to the airway wall can induce alveolar
collapse, what can trigger a fibroproliferation process and
promote the destruction of airways, eventually leading to
severe and irreversible functional impairment (24-26).
Mai et al. 2016 recently used micro-computed tomogra-
phy to analyze the geometric progression of lung changes
caused by IPF, associating the analysis concomitantly with
histopathological and CT findings, and the authors encoun-
tered evidence suggesting that the disease started preferen-
tially at the peripheries of the secondary pulmonary lobules,
gradually extended toward the centrilobular region, and
ultimately replaced the entire lobule (26). The sequence of
lung changes on CT in patients with IPF starts with areas of
GGO that turn into areas of reticulation and end with cystic
changes (26,27). The so-called ‘‘microscopic honeycombing’’
represents the formation of these cystic spaces. These spaces
should be differentiated from the honeycombing visualized
in CT scans; these spaces are present in most cases and are
not necessarily specific to a UIP diagnosis, while honeycom-
bing is highly specific to UIP and is associated with a poor
prognosis (26,28).
When is biopsy necessary? Surgical lung biopsy (SLB)
is the diagnostic method of choice for patients whose imag-
ing findings are not definitive for UIP, including findings
of probable UIP, indeterminate for UIP and alternative
diagnosis. Hence, an integrated multidisciplinary approach
assessing both imaging and pathological features is essential
to establish a final diagnosis (3,6).
Tissue samples should be obtained from two to three
lobes due to the high variability in the distribution and
morphology of abnormalities. Careful evaluation of the pre-
sence of potential risks before performing SLB is essential
as the risks associated with the procedure can outweigh
the benefits of determining a diagnosis, especially in older
patients, in those with severe impairment in PFTs or those
with co-existing comorbidities, such as pulmonary hyperten-
sion and severe heart failure (6,29). Recent evidence suggests
that cryobiopsy is a promising method that is less invasive
than SLB and can be used in place of SLB to obtain lung
samples to confirm an IPF diagnosis (30).
Mimics of idiopathic pulmonary fibrosis
Clinical mimics. Confirmation of an IPF diagnosis is
challenging, requiring the exclusion of pulmonary fibrosis
with known causes, such as asbestosis, CTDs, drug expo-
sure, chronic hypersensitivity pneumonitis (HP), and other
forms of idiopathic interstitial pneumonitis (3,5,6). Although
these entities have similarities with IPF, such as progressive
dyspnea, dry cough, and a restrictive pattern with a decreased
diffusing capacity in the PFT, they are associated with better
prognosis and an improved responsiveness to immunosup-
pressive drugs (7).
Connective tissue diseases. These disorders often affect
young women, and rheumatoid arthritis and systemic sclerosis
are the most common CTDs associated with the UIP pattern.
Extrapulmonary manifestations, such as arthralgia, Sicca
symptoms, Raynaud phenomenon, and esophageal manifesta-
tions, are commonly identiﬁed in ILD associated with CTD.
However, interstitial lung changes can be the sole manifestation
of CTD. The presence of serological abnormalities is an
important feature of CTDs (7). ILD is also associated with
interstitial pneumonia with autoimmune features, which should
be included in the differential diagnosis of IPF (31,32).
Hypersensitivity pneumonitis. HP is an inﬂammatory
syndrome associated with an exposure history to suspected
antigens, such as mold, birds and drugs. Hence, potential
exposures should be extensively investigated in patients with
pulmonary ﬁbrosis. Fatigue, fever, and weight loss may be
found in acute and subacute HP and rarely in those with chronic
forms. Progressive dyspnea is the main symptom in chronic HP,
and inspiratory squeaks on pulmonary auscultation and digital
clubbing may be identiﬁed. If the responsible inhaled antigen can
be identiﬁed, complete avoidance is the most efﬁcient manage-
ment (5,29). Acute disease is commonly self-limited, resolving
without any speciﬁc therapy. Corticosteroid therapy might be
necessary for an acute relief of symptoms and can hasten initial
recovery in severe cases. However, long-term efﬁcacy has not
been demonstrated in prospective clinical trials (33).
Idiopathic nonspeciﬁc interstitial pneumonia. Compared
with IPF, idiopathic NSIP occurs predominantly in young
women and can have associated systemic manifestations, such
as fever, fatigue, and weight loss, and features suggestive of
CTD (4,7,34).
Asbestosis. The main feature for distinguishing asbestosis
from IPF is a history of occupational exposure to asbestos,
Table 2 - Histopathological Criteria for the UIP Pattern.
UIP Probable UIP Indeterminate for UIP Alternative diagnosis
- Evidence of marked
fibrosis / architectural
distortion, ± honey-
combing in a pre-
dominantly subpleural /
paraseptal distribution
- Patchy involvement of lung
parenchyma by fibrosis
- Fibroblast foci
- Some characteristics of





- Absence of features to
suggest an alternative
diagnosis
- Some histologic features of column 1
associated with features that suggest another
diagnosis or UIP secondary to another cause
(granulomas, hyaline membranes, cellular
inflammatory infiltrate in areas away from
honeycombing, prominent lymphoid
hyperplasia, bronchiolocentric distribution,










- Other features suggestive of an
alternate diagnosis
UIP: Usual Interstitial Pneumonia.
Adapted from Raghu et al. (6).
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such as asbestos mining, shipbuilding, and welding. Deter-
mining a temporal association between the exposure and the
occurrence of symptoms is essential (7).
Drug-induced lung diseases. Investigations of exposures to
drugs that can induce ILD, such as bleomycin, amiodarone,
nitrofurantoin, methotrexate, and cyclophosphamide, is essen-
tial in the assessment of patients with a suspicion of IPF.
Determining a temporal relationship between the exposure to
the potential drug and the occurrence of respiratory manifesta-
tions is also necessary (5).
Radiological mimics. NSIP accounts for most of the
disagreements among observers for idiopathic interstitial
pneumonias. HRCT findings that favor NSIP rather than UIP
include the presence of GGOs, which are found in most
cases. Subpleural sparing is highly suggestive of NSIP and
is present in 64% of cases compared to 11% in chronic HP
and 4% in IPF (34). The features that best differentiate
chronic HP from IPF and NSIP are lobular zones with
decreased attenuation, the presence of centrilobular nodules,
and a lack of a lower zone predominance of abnormalities.
The former has been reported in 80% of patients with chronic
HP, 43% of patients with IPF, and 34% of patients with NSIP
(34). The UIP pattern on HRCT in patients with CTDs or
fibrotic HP is similar to the pattern found in idiopathic UIP,
and this should be distinguished on a clinical basis. However,
radiologists may contribute to such differentiation based
on additional findings, such as esophageal dilatation, and
on pleural or pericardial effusion or thickening. Asbestosis
typically has a histologic and HRCT pattern of UIP, and
pleural plaques usually aid in the diagnosis. Fibrotic sarco-
idosis can be distinguished from UIP by the upper lobe,
a predominant peribronchial distribution and other HRCT
findings, including pulmonary nodules, lymph node enlar-
gement and calcifications.
Histopathological mimics. During an examination of an
ILD patient biopsy, the goal of the pathologist is to differ-
entiate UIP from other diseases that may simulate this pattern,
such as CTDs, chronic HP, pneumoconiosis, and NSIP (7,35).
Connective tissue diseases. CTDs are a heterogeneous
group of diseases, with different patterns on biopsy. Although
the most common pattern is an NSIP pattern, UIP is frequently
observed. The presence of an exuberant lymphocytic inﬁltrate
that forms germinal centers and of follicular bronchiolitis can
be helpful features for CTD diagnosis in these situations.
In addition, the presence of pleural ﬁbrosis is more characteristic
of CTDs (7,35).
Chronic hypersensitivity pneumonitis. In chronic HP, ﬁbrosis
is predominantly airway centered but can occasionally manifest
as UIP. Features that might suggest a diagnosis of chronic
HP include a predominance of upper lobes, the presence of
interstitial granulomas, which are mainly peribronchiolar, and
bronchiolitis with peribronchiolar metaplasia (7,35). Recent
studies focusing on genetic factors associated with chronic HP
have suggested a common pathobiology with IPF. A MUC5B
rs35705950 single-nucleotide polymorphism and a short telomere
length, as seen in sporadic and familial forms of IPF, can pre-
dispose patients with HP to lung remodeling and ﬁbrosis (36).
Asbestosis. Asbestosis is histopathologically characterized
by the presence of predominantly subpleural interstitial ﬁbrosis,
which is similar to UIP. However, in early cases, ﬁbrosis can be
more prominent around bronchioles. Other helpful features in
the differential diagnosis with UIP are collagen ﬁbrosis with the
absence of ﬁbroblastic foci and a mild inﬂammatory inﬁltrate.
To conﬁrm the histological diagnosis, asbestos bodies must be
present (37).
Nonspeciﬁc interstitial pneumonia. NSIP is a type of
chronic interstitial pneumonia that is characterized by a relative
spatial homogeneity in the involvement of lung parenchyma,
which is different from the typical patchy pattern of UIP where
regions of the normal lung are interspersed with the affected
parenchyma. In addition, NSIP is characterized by a temporal
homogeneity of lesions (inﬂammation and/or ﬁbrosis), which
is different from the typical temporal heterogeneity of UIP
(7,35,38-41). Other features of UIP, such as smooth muscle
hyperplasia, ﬁbroblastic foci, and an aggregation of elastic
ﬁbers, are not observed in most cases of NSIP (39). In addition,
peripheral accentuation is absent or inconspicuous (41).
Although the UIP pattern may be observed in several ILDs,
there are relevant clinical, tomographic, and histopathologi-
cal features that contribute to differentiating them from IPF.
The diagnosis of IPF is challenging, and a multidisciplinary
discussion with ILD experts, including physicians, radio-
logists, and pathologists, improves the accuracy of the
diagnosis, which is essential to establishing the appropriate
management strategy.
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